Articles On Race Oncology (ASX:RAC)

On a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per cent. The ASX 200 closed 0.56 per cent up at 7,068 points and the ASX Emerging Companies Index rose 0.41 per cent closing at 2,111 points....

Today we will take a look at why we like Race Oncology (ASX RAC). Race Oncology (ASX RAC) is a precision oncology company with a phase II/III cancer drug called Bisantrene. The aim of the company is to build value in Bisantrene through proo...

After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos...

Race Oncology Ltd (ASX: RAC) shares are in a trading halt today as the company seeks to raise an undisclosed amount of capital. At Friday’s close, the Race Oncology share price was trading at $3.07 after significant falls over the past wee...

Summary 5G Networks reported robust growth across all three core products in Q3 FY21 and witnessed a growing demand for the 5GN Voice Bridge One Microsoft Teams product. JB Hi-Fi witnessed double-digit sales growth in two of its three...

Summary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookings in Q3 FY21. ECS Botanics Holdings’ March 2021 quarter was action-packed with a major acquisition and multiple supply agreements. Despit...

Summary Race Oncology Limited has entered into a collaboration for the preclinical study of its cancer drug Bisantrene in heart safety. Advanced Human Imaging has executed a Binding Heads of Agreement for the proposed acquisition of Ph...

The Race Oncology Ltd (ASX: RAC) share price is climbing today after an update from the Aussie healthcare company. Why is the Race Oncology share price climbing? Race Oncology announced that it has entered into a collaborative preclinical...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Race Oncology (ASX:RAC) has announced the appointment of Dr David Fuller as its chief medical officer.

It was another day in the green for the ASX as it edged closer to surpassing the record high it reached immediately prior to COVID-19. The ASX 200 rose 0.51 per cent, closing at 7,058 points while the ASX Emerging Companies Index rose 0.75...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and edging slightly lower. At the time of writing, the benchmark index is down a few points to 7,020 points. Four ASX shares that are not letting that hold them back a...

The Race Oncology Ltd (ASX: RAC) share price has been a very strong performer on Thursday. In morning trade, the precision oncology company’s shares are up 10% to $3.38. Why is the Race Oncology share price storming higher? Investors have...

Another day, another IPO – today the new listee was biotech Island Pharmaceuticals (ASX:ILA). Island Pharmaceuticals is one of the few biotechs fighting mosquito diseases, particularly dengue fever. Its flagship drug ISLA-101 was originally...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the shortened week with a small gain. At the time of writing, the benchmark index is up 0.2% to 6,805.7 points. Four ASX shares that have failed to follow the mark...

Source:WHYFRAME, Shutterstock Summary Huge market volatility has been observed in 2021 so far amid the tug of war between surging COVID-19 cases and progress in economic recovery. Volatility is expected to continue over the coming day...

The Race Oncology Ltd (ASX: RAC) share price is struggling in early-morning trade despite the company announcing the initiation of an extramedullary AML preclinical study. At the time of writing, the specialty pharmaceutical company’s shar...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

The ASX finished the day slightly in the green, dragged down by tech stocks which lost nearly 1.5 per cent and new float Airtasker (ASX:ART) fell by over 20 per cent. Airtasker debuted at 65 cents and rose over Tuesday and Wednesday to over...

Source: Tyler Olson, Shutterstock Summary ASX-listed oncology player Race Oncology to explore the use of Bisantrene for the treatment of ccRCC. 4DMedical to secure contracts with DoD and VA facilities for its XV LVAS with a pre-agreed...

Race Oncology Ltd (ASX: RAC) shares are slipping in late morning trade despite the company providing a positive update. At the time of writing, the Race share price has slumped 1.27% lower to $3.90. Below we take a look at the ASX healthca...

On this day last year, global stocks capped off a historic one-month collapse with another epic fall. While no one knew at the time, that marked the COVID-19 nadir. Over the course of the following week, governments around the world said ju...

Source: Blue Planet Studio, Shutterstock Summary Oncology player Race Oncology has collaborated with the University of Newcastle for its preclinical research program to study Bisantrene in melanoma. Leading Australian diagnostics play...

The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98. Race Oncology share price un...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: fizkes ,Shutterstock Summary Race Oncology announced the positive final results of its preclinical research program for Bisantrene. The results demonstrated that Bisantrene was an effective cancer treatment for genetically dis...

The Race Oncology Ltd (ASX: RAC) share price is 9.4% higher at the time of writing following preclinical breast cancer results.  Race Oncology share price on the move after compelling results  Race Oncology is developing a cancer-fighting...

At the end of January, the GameStop Corp. (NYSE: GME) share price hit an all-time high of US$483. Only 2 months previously, shares in the company were trading at US$14.75. Many attributed the video game retailer’s dramatic rise to subreddi...

Source: ImageFlow,Shutterstock Summary Momentum investing is a relatively newer approach that primarily capitalises on the share price momentum. TPC consolidated has started March 2021 with a bang, delivering 23.81 per cent on Monday....

Source: schankz, Shutterstock Summary The Australian share market’s outlook appears exciting as the economy recovers from the coronavirus-induced disruptions.  The investors could use the opportunity to beef up their portfolios with s...

Hot on the heels of yesterday’s gains, Race Oncology Ltd (ASX: RAC) shares were marching higher again today. By the market’s close, the Race Oncology share price had jumped 2.27% to $3.15. That puts the total gains for the company’s shares...

Race Oncology (ASX:RAC) has released further interim results from its continuing collaborative preclinical research program with The University of Newcastle.

The Race Oncology Ltd (ASX: RAC) share price rocketed 20.98% today, closing the day at $2.48 per share. Race Oncology Ltd (RAC) is an Australian pharmaceutical company with developments in the cancer field. The company produces a chemother...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Summary The intensity of adoption of tech-enabled health solutions has shot up amidst government restrictions and infection risks amidst COVID-19. Burgeoning demand for healthcare products kept healthcare stocks under the spotlight in...

The rebound in the S&P/ASX 200 Index (Index:^AXJO) might be grabbing headlines with its dramatic rebound, but it’s the ASX small caps that’re outperforming. What’s more, the market minnows might keep their lead as we head into 2021 wit...

ShareCafeHidden Gems Webinar Recap – OSP, PYG, AGC, RAC Catch up on the full webinar with presentations from Osprey Medical Inc (ASX: OSP), Paygroup Limited (ASX: PYG), Australian Gold and Copper Limited (ASX:AGC) and Race Oncology Limited...

ShareCafeRace Oncology Limited (ASX:RAC) – Hidden Gems Webinar Presentation Presenter – Dr Daniel Tillett – Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent...

At time of writing the RAC share price is trading at $2.12 up 7.07%. Race Oncology Ltd (ASX:RAC) announced the initiation of a breast cancer clinical trial program... The post Race Oncology Share Price Reaches New High (ASX:RAC) appeared fi...

Race Oncology (ASX: RAC) has shared the results of the preclinical research program it is undertaking as part of a collaboration with The University of Newcastle.

ASX-listed oncology drug developer Race Oncology Limited (ASX:RAC) today updated the market with its impressive results from the preclinical study of Bisantrene in breast cancer. The study results demonstrate that Bisantrene can kill some b...

Race Oncology (ASX: RAC) has unveiled what it describes as “impressive” results in preclinical breast cancer research using its bisantrene drug. The company undertook a collaborative preclinical research program with The University of Newca...

Summary Race Oncology announced that its Phase 2 clinical trial data of bisantrene had been published in the European Journal of Haematology. The results from the clinical study demonstrated an impressive clinical response rate of 40% i...

With biotechnology in focus in 2020, Race Oncology is attracting investor interest. -2020 booming times for (some) biotechnology stocks-Race Oncology aiming to revive 1980’s Acute Myeloid Leukemia (AML) treatment-Bisantrene clinical trials...

Race Oncology (ASX:RAC) has announced it has secured a new patent on its cancer drug, bisantrene, from the US Patent and Trademarks Office.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...